Efficacy and safety of topical tazarotene: a review

Bibliography

• Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs 2008;17(3):437-43
   PubMed Web of Science ®Google Scholar
• Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000;6:919-31
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, et al. International union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-72
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, et al. International union of Pharmacology. LX. Retinoid X receptors. Pharmacol Rev 2006;58:712-25
   PubMed Web of Science ®Google Scholar
• Chandraratna RA. Tazarotene--first of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135(49):18-25
   PubMedGoogle Scholar
• Duvic M, Helekar B, Schulz C, et al. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000;6(8):3249-59
   PubMed Web of Science ®Google Scholar
• Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med 1999;341(23):1767-68
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3(3):193-215
   PubMedGoogle Scholar
• Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. SkinMed 2005;4:138-46
   PubMedGoogle Scholar
• Altinyazar HC, Koca R, Tekin NS, et al. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005;44:252-55
   PubMed Web of Science ®Google Scholar
• Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005;76:145-51
   PubMed Web of Science ®Google Scholar
• Bassiri-Tehrani S, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002;41:104-6
   PubMed Web of Science ®Google Scholar
• Duvic M, Friedman-Kein AE, Galpin J, et al. Phase I-II clinical trial support safety and efficacy of ALRT 1057 Topical retinoid gel for Kaposi sarcoma. Submitted XI International Conference on AIDS. 1996
   Google Scholar
• Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002;47(6):969-7
   PubMed Web of Science ®Google Scholar
• Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005;76:69-73
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910
   PubMed Web of Science ®Google Scholar
• Duvic M, Apisarnthanarax N, Cohen DS. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003;49(1):35-49
   PubMed Web of Science ®Google Scholar
• Taylor PW, Keenan MH. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin 2006;22:603-15
   PubMed Web of Science ®Google Scholar
• Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002:8:1234-40
   PubMed Web of Science ®Google Scholar
• Smit JV, Franssen ME, de Jong EM, et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004;51:249-56
   PubMed Web of Science ®Google Scholar
• Smit JV, de Jong EM, van Hooijdonk CA, et al. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 2004;51:257-64
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Stevens V, Sheth P, et al. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004;150:545-53
   PubMed Web of Science ®Google Scholar
• Talpur R, Vu J, Bassett R, et al. Phase I/II Randomized Bilateral Half-Head Comparison of Topical Bexarotene 1% Gel for Alopecia Areata. Unpublished data
   Google Scholar
• Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995;133:426-32
   PubMed Web of Science ®Google Scholar
• Vahlquist A, Duvic M. Retinoids and carotenoids in dermatology. first edition. Informa Healthcare; 2007
   Google Scholar
• Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999;37(4):273-87
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92
   PubMed Web of Science ®Google Scholar
• Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double blind, vehicle controlled study. Cutis 1999;63:349-54
   PubMed Web of Science ®Google Scholar
• Chen DS, Sandri RB, Tang Liu DDS. Systemic pharmacokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. Drug Metab Disp 1992;20:211-17
   PubMed Web of Science ®Google Scholar
• Lippman SM, Glisson BS, Kavanagh JJ, et al. Retinoic acid and interferon combination studies in human cancer. Eur J Cancer 1993;29A(Suppl 5):S9-13
   PubMed Web of Science ®Google Scholar
• DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA 1998;95(25):14811-5
   PubMed Web of Science ®Google Scholar
• Duvic M. Tazarotene: a review of its pharmacological profile. Exp opin invest Drugs 1997;6(10):1573-51
   Google Scholar
• Study report PK-1989-032. Transdermal permeation, disposition and bioconversion of SKF 190168 from one gel formulation using human fresh skin, human cadaver skin and fuzzy rat skin as skin barrier. Irvine (CA): Allergan, 1989
   Google Scholar
• Study report PK-1993-013. Percutaneous absorption and mass balance of 14C-AGN 190168 0.1% gel following topical administration to healthy subjects (clinical study R168-150-7997). Irvine (CA): Allergan, 1993
   Google Scholar
• Franz TJ, Lehman PA, Franz SL, et al. Percutaneous absorption of AGN 190168, a new synthetic retinoid, through human skin in vivo. J Invest Dermatol 1992;98:650
   Google Scholar
• Kruger JG. The immunologic basis for the treatment of psoriasis with the new biologic agents. J Am Acad Dermatol 2002;46:1-23
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9(2):136-39
   PubMed Web of Science ®Google Scholar
• Kenney JA. Psoriasis in the American black. In: Farber EM, Cox AJ, editors, Psoriasis: proceedings of the International Symposium, Stanford University. Stanford, Calif.: Stanford University Press, 1971. p. 49-52
   Google Scholar
• Christophers E. Psoriasis- epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20
   PubMed Web of Science ®Google Scholar
• Thaci D. Long-term data in the treatment of psoriasis. Br J Dermatol 2008;159(2):18-24
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retionid for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48(5):760-7
   PubMed Web of Science ®Google Scholar
• Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen J, et al. Once daily tazarotene gel versus twice daily floucinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-11
   PubMed Web of Science ®Google Scholar
• Guenther L. Tazarotene combination treatment in psoriasis. J Am Acad Dermatol 2000;43:S31-S35
   PubMed Web of Science ®Google Scholar
• Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001;40:210-12
   PubMed Web of Science ®Google Scholar
• Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000;22:1225-38
   PubMed Web of Science ®Google Scholar
• Behrens S, Grundmann-Kollman M, Schiener R, Peter Ru Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000;42:493-95
   PubMed Web of Science ®Google Scholar
• Gollnick H, Menter A. A combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;40(54):18-23
   Google Scholar
• Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment; comparison of maintenance treatments. Int J Dermatol 2001;40:64-6
   PubMed Web of Science ®Google Scholar
• Green L, Sadoff W, Lebwohl MG, et al. A clinical evaluation of tazarotene 0.1% gel with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002;30:95-102
   Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaques psoriasis. J Am Acad Dermatol 1998;39:590-96
   PubMed Web of Science ®Google Scholar
• Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002;46:907-13
   PubMed Web of Science ®Google Scholar
• Stuttgen G. Zur Lokal behandlung von keratosen mit Vitamin A-Säure. Dermatologica 1962;124:65-80
   PubMedGoogle Scholar
• Saurat JH, Hirschel-Scholz S, Salomon D. Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link. Dermatologica 1987;175(1):13-19
   PubMedGoogle Scholar
• Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus Tazarotene plus Clindamycin/Benzoyl Peroxide in the Treatment of Acne Vulgaris: A Multicenter, Double-Blind Randomized Parallel-Group Trial. J Drugs Dermatol 2006;5(3):256-61
   PubMedGoogle Scholar
• Shalita AR, Berson DS, Thiboutot DM, et al. Effects of Tazarotene 0.1% Cream in the Treatment of Facial Acne Vulgaris: Pooled Results from Two Multicenter, Double-blind, Randomized, Vehicle-Controlled, Parallel-Group Trials. Clin Ther 2004;26(11):1865-73
   PubMed Web of Science ®Google Scholar
• Wauben-Penris PJ, Cerneus DP, van den Hoven WE, et al. Immunomodulatory effects of tretinoin in combination with clindamycin. J Eur Acad Dermatol Venereol 1998;11(Suppl 1):S2-7; discussion S28-9
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Ioannides D, Kalogeromitros D, Katsambas AD. Comparison of Topical Retinoids in the Treatment of Acne. J Clin Dermatol 2004;22:408-11
   PubMed Web of Science ®Google Scholar
• Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 2003;4:197-202
   PubMed Web of Science ®Google Scholar
• Thielitz A, Naser MB, Fluhr JW, et al. Topical Retinoids in Acne – an Evidence-based overview. J Dtsch Dermatol Ges 2008;6
   PubMedGoogle Scholar
• Pariser D, Colon L, Johnson L, Gottschalk R. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drug Dermatol 2008;7(6):S18(6)
   PubMed Web of Science ®Google Scholar
• Kakita L. Tazarotene versus tretinoin or adalpane in the treatment of acne vulgaris. Presented at the Symposium “New directions in the treatment of psoriasis, acne, and skin aging.” J Am Acad Dermatol 2000;43:S51-4
   PubMed Web of Science ®Google Scholar
• Bershad S, Kranjac Singer G, Parente JE. Successful treatment of acne vulgaris using a new method. Results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002;138:481-9
   PubMed Web of Science ®Google Scholar
• Leyden J. Split-face evaluation of the facial tolerability of tazarotene gel compared with tretinoin gels and adapalene gel. Poster presented at the 58th Annual Meeting of the American Academy of Dermatology, March 10-15, 2000, San Francisco, CA
   Google Scholar
• Leyden J. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. Cutis 2004;74(Suppl 4):4-8
   Google Scholar
• Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001;67:10-16
   PubMedGoogle Scholar
• Gold LS, Colón LE, Johnson LA, Gottschalk RW. Is switching retinoids a sound strategy for the treatment of acne vulgaris? J Drugs Dermatol 2008;7(6):11-7
   Google Scholar
• Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris: A Multicenter, Double-blinded, Randomized, Parallel- Group Study. Arch Dermatol 2006;142:605-12
   PubMed Web of Science ®Google Scholar
• Gilchrest BA. A review of skin aging and its medical therapy. Br J Dermatol 1996;135:867-75
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Int Aging 2006;1(4):327-48
   PubMed Web of Science ®Google Scholar
• Kang S, Fisher GJ, Voorhees JJ. Photoaging: Pathogenesis, prevention, and treatment. Clin Ger Med 2001;17:643-59
   PubMed Web of Science ®Google Scholar
• Lavker RM, Klingman AM. Chronic heliodermatitis: a morphologic ealuation of chronic dermal damage with emphasis on the role of mast cells. J Invest Dermatol 1988;266:17662-6
   Google Scholar
• Rittié L, Fisher GJ. UV-light-induced signal cascades and skin aging. Aging Res Rev 2002;1:705-20
   PubMed Web of Science ®Google Scholar
• Massague J. TGF-β signal transduction. Ann Rev Biochem 1998;67:753-91
   PubMed Web of Science ®Google Scholar
• Griffiths CE. Dowling Oration delivered at the Royal College of Physicians, London, Retinoids: renaissance and reformation. Clin Exp Dermatol 1998;24:329-35
   Web of Science ®Google Scholar
• Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoid acid receptor alpha. J Biol Chem 1995;270:923-7
   PubMed Web of Science ®Google Scholar
• Chandraratna RA. Tazarotene - first of a new generation of receptor – selective retinoids. Br J Dermatol 1996;135(49):18-25
   PubMedGoogle Scholar
• Machtinger LA, Kaidbey K, Lim J, et al. Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, milticentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin. Br J Dermatol 2004;151:1245-52
   PubMed Web of Science ®Google Scholar
• Kang S, Krueger GG, Tanghetti EA. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol 2005;52(2):268-74
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% Tazarotene Cream for the Treatment of Photodamage: A 12-Month Multicenter, Randomized Trial. Arch Dermatol 2002;138:1486-93
   PubMed Web of Science ®Google Scholar
• Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene Cream for the Treatment of Facial Photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001;137:1597-604
   PubMed Web of Science ®Google Scholar
• Lowe N, Gifford M, Tanghetti E, et al. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther 2004;6:79-85
   PubMedGoogle Scholar
• Lowe N, Horwitz S, Tanghetti E, et al. Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. J Cosmet Laser Ther 2006;8:121-27
   PubMedGoogle Scholar
• Taylor S. Tazarotene in the treatment of pseudofolliculitis barbae in patients with skin color: an investigator masked, split-face, placebo controlled, parallel group study. Poster presented at: American Academy of Dermatology Summer Meeting; July 31 – August 4, 2002; New York. p. 26
   Google Scholar
• Tsuchiya AM. Tazarotene in the management of epidermal nevi. Poster presented at 60th Annual meeting of the American Academy of Dermatology; Feburary 22 – 27, 2002; New Orleans, LA. p. 190
   Google Scholar
• Weisshar E, Bonnekoh B, Franke I, et al. Successful symptomatic tazarotene of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance. Hautarzt 2001;52:499-503
   PubMed Web of Science ®Google Scholar
• Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis 2006;77(1):45-50
   PubMed Web of Science ®Google Scholar
• Patterson WM, Fox MD, Schwartz RA. Favre-Racouchot Disease. Int J Dermatol 2004;43:167-69
   PubMed Web of Science ®Google Scholar
• Rallis E, Karanikola E, Verros C. Successful treatment of Favre-Racouchot Disease with 0.05% tazarotene gel. Arch Dermatol 2007;143:810-12
   PubMed Web of Science ®Google Scholar
• Gerbig AW. Treating keratosis pilaris. J Am Acad Dermatol 2002;47(3):457
   PubMed Web of Science ®Google Scholar
• Nguyen V, Cunningham B, Eichenfield L, et al. Treatment of ichthosiform diseases with topically applied tazarotene: risk of systemic absorption. J Am Acad Dermatol 2006:57(5):S123-4
   Web of Science ®Google Scholar
• Yoo S, Simzar S, Han K, et al. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Pediatr Dermatol 2006;23(4):382-85
   PubMed Web of Science ®Google Scholar
• Wolbach SB, Howe PR. Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 1925;43:753
   Google Scholar
• Teherani DK, Parissa M, Tanwew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Ped Dermatol 2008;25:125-6
   PubMed Web of Science ®Google Scholar
• Naineni KK, Hohle R, Lucke T. Disseminated superficial actinic porokeratosis of the scalp. Clin Exp Dermatol 2007;32(2):222-3
   PubMed Web of Science ®Google Scholar
• Rand R, Baden HP. Commentary: Darier-White disease. Arch Dermatol 1983;119:81-3
   PubMed Web of Science ®Google Scholar
• Itin PH, Büchner SA, Happle R. Segmental manifestation of Darier disease. Dermatol 2000;200:254-7
   PubMed Web of Science ®Google Scholar
• Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998;38:1001-2
   PubMed Web of Science ®Google Scholar
• Oster-Schmidt. The treatment of Darier's disease with topical tazarotene. Br J Dermatol 1999;141:603-4
   PubMed Web of Science ®Google Scholar
• Micali G, Nasca MR. Tazarotene gel in childhood Darier disease. Pediatr Dermatol 1999;16:243-4
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Prestinari F, Barbagallo T, et al. Linear Darier's disease successfully treated with 0.1% tazarotene gel “short-contact” therapy. Eur J Dermatol 2006;16(1):59-61
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 2004;50(4):600-7
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(61):1-6
   PubMed Web of Science ®Google Scholar
• Marghoob AA. Basal and squamous cell carcinomas: what every primary care physician should know. Postgrad Med 1997;102:139-59
   PubMed Web of Science ®Google Scholar
• Vine JE. Skin cancer update. Treatment alternatives for basal-cell and squamous-cell carcinoma. N J Med 2001;98:35-7
   PubMedGoogle Scholar
• Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004;151(1):148-56
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Bianchi F, Parente G, et al. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol 2005;52(6):1102-4
   PubMed Web of Science ®Google Scholar
• Ofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999;141:642-6
   PubMed Web of Science ®Google Scholar
• Pedersen NB. Persistent occupational koilonychia. Contact Dermatitis 1982;8:134
   PubMed Web of Science ®Google Scholar
• Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001;68:355-8
   PubMed Web of Science ®Google Scholar
• Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel in finger and toenail psoriasis: a prospective open study. Br J Dermatol 2003;149(1):207-9
   PubMed Web of Science ®Google Scholar
• Hagman JH, Ginebri A, Mordenti C, et al. Treatment of Occupational Koilonychia with Tazarotene Gel. Acta Derm Venereol 2003;83:296-7
   PubMed Web of Science ®Google Scholar
• Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene montherapy and combination therapies in psoriasis. Expert Opin Pharmacothe 2003;4(12):2347-54
   PubMed Web of Science ®Google Scholar
• Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000;43:S31-S35
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/pro/tazorac.html. Tazorac Gel package insert (Allergan Herbert–US), Rev 6/97, Rec 6/97
   Google Scholar
• Life Science. Allergan psoriasis treatment tazarotene denied approval by FDA. Available from: www.newsrx.com/newsletters/Life-Science-Weekly. [Accessed 31 October 2008]
   Google Scholar
• van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19(5):252-63
   PubMed Web of Science ®Google Scholar